^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NXP800

    i
    Company:
    Cancer Therapeutics CRC, Nuvectis Pharma
    Drug class:
    GCN2 activator
    Related drugs:
    Apply
    A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101) (NCT05226507)
    Phase 1
    Nuvectis Pharma, Inc.
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/31/2021
    Primary completion :
    05/01/2025
    Completion :
    12/01/2025
    ARID1A • BRCA
    |
    ARID1A mutation • BRCA mutation
    |
    NXP800